



# Qualitäts- und Dokumentationsanforderungen für die intrakranielle Stereotaktische Strahlentherapie

***Dr. Oliver Blanck***

*Research Coordinator*

*UKSH, Department of Radiation Oncology, Kiel, Germany*

*Chief Operating Officer, Head of Medical Physics, Research and  
Development, Saphir Radiosurgery (Frankfurt and Kiel)*

# Hintergrund Inhomogener Dosisverteilungen




## Klinisch-Biologische Überlegungen

→ Deutliche Evidenz für Hirn-Metastasen

- ❖ Prädiktoren für bessere Lokalkontrolle:
  - Tumorgröße
  - Inhomogene Dosisverteilung
- ❖ Prädiktoren für weniger Radionekrose
  - Geringe Anzahl an Metastasen
  - Inhomogene Dosisverteilung

**Table 2**  
Dosimetric parameters.

	Group 1		Group 2	
	N = 91	Median (range) %	N = 43	Median (range)
D <sub>98%</sub>		23.1 Gy (21–23.1)		23.3 Gy (21–23.8)
D <sub>2%</sub>		24.8 (22.5–25.2)		32.9 (29.8–33.2)
D <sub>50%</sub>		24.2 (21.2–25.4)		28.1 (27.7–29.8)
V <sub>5Gy</sub> (brain)		105.9 (43.2–184.8)		104.3 (42.4–172.5)
V <sub>10Gy</sub> (brain)		9.63 (4.83–29.1)		9.07 (4.42–24.51)
V <sub>12Gy</sub> (brain)		3.22 (0.45–9.31)		2.71 (0.15–6.21)
V <sub>21Gy</sub> (brain)		0.83 (0–2.42)		0.79 (0–2.31)
Target coverage		99.0 (95.4–100)		98.9 (95.3–100)
Conformity Index		1.33 (1.05–1.62)		1.32 (1.06–1.61)
SRT dose				
• 23.1 Gy in 3 fractions	101/136	81.7	59/72	
• 21 Gy in 3 fractions	25/136	18.3	13/72	



Number at risk  
Group: 1



136 127 120 110 88 72 54

Group: 2

72 72 71 71 64 41 31

# Hintergrund Inhomogener Dosisverteilungen

→ Physikalische Überlegungen



# Qualitätsanforderungen für die SRS/FSRT

Strahlenther Onkol

<https://doi.org/10.1007/s00066-020-01603-1>

CONSENSUS STATEMENT

## Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery

Matthias Guckenberger<sup>1</sup> · Wolfgang W. Baus<sup>2</sup> · Oliver Blanck<sup>3</sup> · Stephanie E. Combs<sup>4</sup> · Jürgen Debus<sup>5</sup> · Rita Engenhart-Cabillic<sup>6</sup> · Tobias Gauer<sup>7</sup> · Anca L. Grosu<sup>8</sup> · Daniela Schmitt<sup>5</sup> · Stephanie Tanadini-Lang<sup>1</sup> · Christos Moustakis<sup>9</sup>

## Stereotactic Radiosurgery (SRS):

Intracranial malignant or benign tumors and functional or vascular disorders with one single irradiation fraction

## Fractionated Stereotactic Radiotherapy (FSRT):

Intracranial malignant or benign tumors and functional or vascular disorders

## Stereotactic Body Radiotherapy (SBRT):

Extracranial malignant or benign tumors and functional or vascular disorders



Strahlenther Onkol

<https://doi.org/10.1007/s00066-020-01583-2>

REVIEW ARTICLE

## Technological quality requirements for stereotactic radiotherapy

Expert review group consensus from the DGMP Working Group for Physics and Technology in Stereotactic Radiotherapy

Daniela Schmitt<sup>1</sup> · Oliver Blanck<sup>2</sup> · Tobias Gauer<sup>3</sup> · Michael K. Fix<sup>4</sup> · Thomas B. Brunner<sup>5</sup> · Jens Fleckenstein<sup>6</sup> · Britta Loutfi-Krauss<sup>7</sup> · Peter Manser<sup>4</sup> · Rene Werner<sup>8</sup> · Maria-Lisa Wilhelm<sup>9</sup> · Wolfgang W. Baus<sup>10</sup> · Christos Moustakis<sup>11</sup>

Original article

Strahlenther Onkol 2014 · 190:521–532  
DOI 10.1007/s00066-014-0648-7  
Received: 21 January 2014  
Accepted: 25 February 2014  
Published online: 9 April 2014  
© Springer-Verlag Berlin Heidelberg 2014

Martin Kocher<sup>1</sup> · Andrea Wittig<sup>2</sup> · Marc Dieter Piroth<sup>3,9</sup> · Harald Treuer<sup>4</sup> · Heinrich Seegenschmied<sup>5</sup> · Maximilian Ruge<sup>4</sup> · Anca-Ligia Grosu<sup>6</sup> · Matthias Guckenberger<sup>7,8</sup>

<sup>1</sup>Department of Radiation Oncology, University Hospital Cologne, Köln, Germany

<sup>2</sup>Department of Radiotherapy and Radiation Oncology, Philips-University Marburg, Marburg, Germany

<sup>3</sup>Department of Radiotherapy and Radiation Oncology, University Hospital RWTH Aachen, Aachen, Germany

<sup>4</sup>Department of Stereotaxy and Functional Neurosurgery, University Hospital Cologne, Köln, Germany

<sup>5</sup>Radioonkologie und Strahlentherapie, Strahlencentrum Hamburg, Hamburg, Germany

<sup>6</sup>Department of Radiation Oncology, University Hospital Freiburg, Freiburg, Germany

<sup>7</sup>Department of Radiation Oncology, University of Würzburg, Würzburg, Germany

<sup>8</sup>Department of Radiation Oncology, University Hospital Zurich, Zürich, Switzerland

<sup>9</sup>Klinik für Strahlentherapie und Radio-Onkologie, Helios-Klinikum Wuppertal, Wuppertal, Germany

## Stereotactic radiosurgery for treatment of brain metastases



A report of the DEGRO Working Group on Stereotactic Radiotherapy



# Qualitätsanforderungen für die SRS/FSRT

## Imaging for target volume definition

- The target volume and all organs-at-risk are defined using **organ-specific imaging modalities** and standardized imaging protocols dedicated for stereotactic radiotherapy procedures
- The use of secondary imaging requires **accurate** registration with the **thin-slice** planning computed tomography



# Qualitätsanforderungen für die SRS/FSRT

## Patient positioning and target volume localization


Daily in-room image-guidance and online correction of target position errors using **on-board CT**, supplementary **in-room CT** or **stereoscopic X-ray** is required:

- SRS: Invasive fixation using a stereotactic head frame can be used alternatively to image guidance
- SRS and FSRT: Non-invasive fixation of the patient's head is combined with image-guidance

## Motion management

Systematic assessment and consistent consideration of periodic and non-periodic target motion during:

- Imaging for treatment planning;
- Target volume definition;
- Beam-delivery technique planning;
- Dose simulation;
- Target volume localization & repositioning; and
- **Dose application**



Source: Kataria T, et al. Analysis of intrafraction motion in CyberKnife-based stereotaxy using mask based immobilization and 6D-skull tracking. J Radiosurg SBRT. 2016;4(3):203-212. Kang CL, et al. Comparison of Skull Motions in Six Degrees of Freedom Between Two Head Supports During Frameless Radiosurgery by CyberKnife. Front Oncol. 2018 4;8:359.

# Qualitätsanforderungen für die SRS/FSRT


## Collimation of the irradiation and beam directions

For the respective treatment modalities, collimation and beam direction requires the following characteristics: **SRS** with multileaf collimator (MLC) with leaf width **5mm** or cylindrical collimators of equivalent size, [...], and used with systems allowing **non-coplanar beam directions**. **FSRT** with MLC with leaf width **6.5mm** or cylindrical collimators of equivalent size, both at normal treatment distance.

## Dose calculation

For stereotactic radiotherapy in areas with large **density inhomogeneities** the use of a dose calculation algorithm that takes into account lateral electron transport to **correct for density inhomogeneities** is required.

The maximum grid size for dose calculation should be 1–2mm according to the target lesion dimensions and the image resolution for target definition




# Qualitätsanforderungen für die SRS/FSRT

## Treatment unit accuracy

A geometric accuracy with three-dimensional spatial dose placement in **system-specific end-to-end tests** requires inaccuracies of at maximum: **1mm for SRS, 1.25mm for FSRT** and SBRT in non-moving phantoms, and 1.5mm for SBRT in moving phantoms. However, for **FSRT** and SBRT **close** to radiation-sensitive critical structures the **same** geometric accuracy requirement as for SRS is recommended. A **dosimetric accuracy** with point-based plan-to-measurement differences of **maximum 3%** within a target volume of more than or equal to 2cc [..]

## Dedicated quality assurance measures

- Small field dosimetry for commissioning.
- System-specific end-to-end testing for both static and moving target volumes.
- Regular check of the geometric and dosimetric accuracy according to system-specific guidelines.
- Day-to-day quality control of the consistency of the stereotactic frame and/or the image-guidance system isocenter with the treatment beam isocenter.





# Qualitätsanforderungen für die SRS/FSRT

## Process quality requirements

- Written **standard operating procedures** for all stereotactic radiotherapy relevant process steps are required
- **Interdisciplinary** discussions on the indication for stereotactic radiotherapy are required
- A **trained** multiprofessional stereotactic radiotherapy project team (radio-oncology, medical physics, radiation therapists) for the implementation and application of SRS/FSRT/SBRT is required
- **Sufficient experience** in stereotactic radiotherapy with **≥ 20 patients** treated each year with SRS, FSRT and SBRT (experiences gained in SRS can be transferred to FSRT) is required
- **Prescribing, recording and reporting** each SRS/FSRT/SBRT treatment procedure according to international guidelines and standards is required (ICRU91)

# Dokumentationsanforderungen für die SRS/FSRT

**Rx = 91%**

Sequential Optimization is complete. The total optimization process took: 2 minute(s) 23 second(s)

VOI	Min (cGy)	Mean (cGy)	Max (cGy)	CI	nCI	HI	Coverage
CTV	1760.67	1914.53	1956.52	1.59	n/a	n/a	n/a
Brain Stem	0.00	64.90	338.47	n/a	n/a	n/a	n/a
Innenohr Links	21.73	51.17	78.88	n/a	n/a	n/a	n/a
PTV	1760.67	1890.42	1956.52	1.05	n/a	n/a	n/a
30mm	0.00	142.61	1856.19	n/a	n/a	n/a	n/a
15mm	0.14	403.18	1856.19	n/a	n/a	n/a	n/a
Epidermis	0.00	33.42	163.24	n/a	n/a	n/a	n/a
[PTV] Shell 1	824.84	1110.74	1253.54	n/a	n/a	n/a	n/a
[PTV] Shell 2	0.14	167.55	308.29	n/a	n/a	n/a	n/a
[PTV] Shell 3	0.00	50.49	153.49	n/a	n/a	n/a	n/a

**Rx = 60%**

Sequential Optimization is complete. The total optimization process took: 2 minute(s) 41 second(s)

VOI	Min (cGy)	Mean (cGy)	Max (cGy)	CI	nCI	HI	Coverage
CTV	1938.99	2402.72	3000.00	1.71	1.71	1.67	100.00%
Brain Stem	0.00	56.80	284.28	n/a	n/a	n/a	n/a
Innenohr Links	14.80	45.42	97.69	n/a	n/a	n/a	n/a
PTV	1799.95	2252.70	3000.00	1.12	1.12	1.67	99.71%
30mm	0.00	114.23	1984.31	n/a	n/a	n/a	n/a
15mm	0.00	320.86	1984.31	n/a	n/a	n/a	n/a
Epidermis	0.00	27.49	122.08	n/a	n/a	n/a	n/a
[PTV] Shell 1	619.03	856.90	972.20	n/a	n/a	n/a	n/a
[PTV] Shell 2	0.00	132.82	225.28	n/a	n/a	n/a	n/a
[PTV] Shell 3	0.00	40.64	101.00	n/a	n/a	n/a	n/a

# Dokumentationsanforderungen für die SRS/FSRT

## ICRU Report 91

- Verschreibung auf „Surrounding Isodose Surface“
- Level 2 Reporting für Margins, Min/Max/Median Dose ...

**Level 2:**  
Advanced Techniques


DVHs calculated  
PTV:  $D_{50\%}$ ,  $D_{\text{near-min}}$ ,  $D_{\text{near-max}}$   
GTV/CTV/ITV:  $D_{50\%}$  must for Lung  
OAR/PRV: Vol,  $D_{\text{mean}}$ ,  $V_D$ ,  $D_{2\%}$   
Dose Homogeneity and  
Conformity and Gradient Index



ICRU Report 91 on Prescribing, Recording, and Reporting of Stereotactic Treatments with Small Photon Beams

A Statement from the DEGRO / DGMP Working Group Stereotactic Radiotherapy and Radiosurgery

Lotte Wilke (PhD)<sup>1\*</sup>, Nicolaus Andratschke (MD)<sup>1</sup>, Oliver Blanck (PhD)<sup>2</sup>,  
Thomas B. Brunner (MD)<sup>3</sup>, Stephanie Combs (MD)<sup>4</sup>, Anca-Ligia Grosu (MD)<sup>5</sup>,  
Christos Moustakis (PhD)<sup>6</sup>, Daniela Schmitt (PhD)<sup>7</sup>, Wolfgang Baus (PhD)<sup>8</sup>,  
Matthias Guckenberger (MD)<sup>1</sup>



# Dokumentationsanforderungen für die SRS/FSRT

## ICRU Report 91: Beispiel SRS einer Hirnmetastase

The screenshot shows the Accuray software interface with a plan summary window open. The plan name is '1x20Gy\_60\_HMx\_0922'. The status is 'Deliverable'. The treatment machine is 'C234 / C0234'. The plan was saved on '19 Sep 2022, 5:10:11 PM'. The collimator type is 'Fixed' and the anatomy is 'head\_iris-fixed'. The path set is 'Full\_Path'. The dose calculation algorithm is 'Ray Trace (3D)'. The contour correction is 'Yes' and the optimization algorithm is 'Sequential'. The estimated delivery time is 48 minutes, with 177 non-zero beams, n/a segments with MU, 140 imaging beams, and 0 zero-dose beams.

<b>Plan Name:</b>	1x20Gy_60_HMx_0922
<b>Plan Status:</b>	Deliverable
<b>Plan Type:</b>	Standard
<b>Treatment Machine / Serial No.:</b>	C234 / C0234
<b>Plan Saved Date:</b>	19 Sep 2022, 5:10:11 PM (hr:min:sec)
<b>Collimator Type:</b>	Fixed
<b>Anatomy:</b>	head_iris-fixed
<b>Path Set:</b>	Full_Path
<b>Dose Calculation Algorithm:</b>	Ray Trace (3D)
<b>Contour Correction:</b>	Yes
<b>Optimization Algorithm:</b>	Sequential
<b>Estimated Delivery Time (min):</b>	48
<b>Number of Non-zero Beams:</b>	177
<b>Number of Segments with MU:</b>	n/a
<b>Number of Imaging Beams:</b>	140
<b>Number of Zero-dose Beams:</b>	0

VOI List

VOI	Volume (cm <sup>3</sup> )	Min (cGy)	Mean (cGy)	Max (cGy)	CI	nCI	HI	Coverage %	Beam Inter.
GTV1	0.58	1912	2606	3333	1.07	1.08	1.67	98.45	n/a
Auge Links	10.80	11	13	14	n/a	n/a	n/a	n/a	Never
Auge Rechts	10.77	11	13	19	n/a	n/a	n/a	n/a	Never
Linse Links	0.17	12	12	13	n/a	n/a	n/a	n/a	Never
Linse Rechts	0.16	12	13	13	n/a	n/a	n/a	n/a	Never
Hirnstamm	23.45	10	11	22	n/a	n/a	n/a	n/a	Never
Ganzhirn	1419.35	10	36	3333	n/a	n/a	n/a	n/a	Allowed
Chiasma Opticum	0.31	12	12	16	n/a	n/a	n/a	n/a	Never
Sehnerv Links	0.85	11	12	13	n/a	n/a	n/a	n/a	Never
Sehnerv Rechts	0.76	12	12	14	n/a	n/a	n/a	n/a	Never
Hypophyse	0.68	11	12	16	n/a	n/a	n/a	n/a	Never
Innenohr Links	1.26	11	11	12	n/a	n/a	n/a	n/a	Never
Innenohr Rechts	1.26	11	11	12	n/a	n/a	n/a	n/a	Never
PreSRS_0621	0.43	20	24	28	n/a	n/a	n/a	n/a	Never
PTV1	0.58	1912	2606	3333	1.07	1.08	1.67	98.45	n/a
Boost	0.11	2933	3164	3333	5.58	5.58	1.67	100.00	n/a
Block	65.10	8	9	10	n/a	n/a	n/a	n/a	Never
* Epidermis	1298.92	8	15	302	n/a	n/a	n/a	n/a	Allowed
* Body	5896.18	8	20	3333	n/a	n/a	n/a	n/a	Allowed
[PTV1] Shell 3	7.22	32	79	193	0.00	0.00	0.00	0.00	Allowed
[PTV1] Shell 2	3.09	48	158	257	0.00	0.00	0.00	0.00	Allowed
[PTV1] Shell 1	0.61	443	744	849	0.00	0.00	0.00	0.00	Allowed
All Target Regions	n/a	1912	2606	3333	1.07	1.08	1.67	98.45	n/a
All Critical Regions	n/a	8	26	3333	n/a	n/a	n/a	n/a	n/a
Soft Tissue	n/a	8	15	1143	n/a	n/a	n/a	n/a	n/a

# Zusammenfassung

- Klare **Qualitätskriterien** für die **GESAMTE** Behandlungskette der Stereotaktischen Strahlentherapie (SRS ≤ FSRT ≤ SBRT) durch DEGRO und DGMP **etabliert**
- Diese werden **TEIL** der überarbeiteten **DIN Norm** Stereotaktische Strahlentherapie (in Arbeit), der **Ärztlichen Stelle Prüfungen** (im engen Austausch) und der **Abrechnung** für die Stereotaktische Radiochirurgie im Rahmen des EBM (Anforderungen nach Vorlage des GBA)
- **Kernmerkmale der Qualitätskriterien** für die Stereotaktische Strahlentherapie:
  - Voraussetzungen und Prozessstrukturen (Training, SOPs, etc.)
  - Bildgebung/-registrierung und Konturierung (und Unsicherheiten)
  - Technische und klinische Genauigkeiten (und deren Messung)
  - Dokumentation und Nachsorge (1 x 20 Gy ≠? 1 x 20 Gy)
- **Vision: Innovative Radioonkologie im Team – präzise, personalisiert, menschlich**